Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
Which GLP-1RA provides better benefits?
Read More »Comparisons of GLP-1 Agonists
Liraglutide Use in Youth with Type 2 Diabetes
Results from a phase 3 trial investigating the use of liraglutide in children and adolescents.
Read More »Insulin Glargine/Lixisenatide vs. Insulin Glargine for T2DM
A better understanding of clinical characteristics can lead to more effective therapy being implemented earlier, and fewer complications.
Read More »Why Add A GLP-1 Agonist To Existing Treatment for Type 2 Diabetes?
Adding Dulaglutide, Liraglutide or Semaglutide (GLP-1 agonists) to existing treatment for type 2 diabetes has major cardiovascular benefits. Exenatide* and Lixisenatide were neutral for providing cardiovascular benefits.
Read More »Head-to-Head Comparison: Oral Semaglutide vs. Empagliflozin
The first oral glucagon-like peptide receptor agonist recently gained FDA approval, but how does it compare to oral agents already on the market?
Read More »A New Medication Class for Children with Diabetes
The results of a recent phase III study may offer children with diabetes a new route for better glycemic control.
Read More »Benefits of Using GLP-1 Receptor Agonists in Type 2 Patients
The use of GLP-1 receptor agonists in patients may prevent multiple risks.
Read More »FDA Approves First Oral GLP-1 Treatment for Type 2 Diabetes, But Wait!
Unique directions for taking the pill may cause a compliance issue; it's not as simple as just taking a pill once a day.
Read More »EXCEED Trial: Efpeglenatide Displays Significant Reduction in HbA1c and Body Weight
Efpeglenatide, a new GLP-1 receptor agonist, referenced to liraglutide in Phase II trial.
Read More »Oral Semaglutide – A Phase 3 Trial in Patients with Type 2 Diabetes
Final results from a phase 3 study preceded FDA approval of oral semaglutide.
Read More »